CD8A and neoplasm: To test whether the generation of tumor-reactive T cells was affected by dual treatment, we isolated cells from tumor, drain lymph node, or spleen of mice received therapy, stimulated ex vivo with either DMSO (control) or gp100 (B16-F10 tumor-associated antigen), and then assessed IFN-γ producing CD8+ T cells.